ZENPEP
LOE Approachingpancrelipase lipase, pancrelipase protease, pancrelipase amylase
BLAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZENPEP is an oral delayed-release pancreatic enzyme replacement therapy containing lipase, protease, and amylase for digestive support. It is indicated for patients with pancreatic insufficiency who cannot adequately digest food due to insufficient endogenous pancreatic enzyme production. The product works by supplementing missing digestive enzymes to improve nutrient absorption.
$0.39MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D penetration signals transition planning and potential role consolidation on the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZENPEP supports a small, specialized team with 6 linked positions predominantly in R&D and Commercial functions. Working on this product offers exposure to mature brand management, competitive positioning, and regulatory navigation in the enzyme therapy space.
AlternantAlternance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.